Biopôle Lausanne

📣 The results are in! Switzerland ranks first among the 133 economies featured in the Global Innovation Index 2024. Other key takeaways: 🥈 Switzerland ranks second in innovation inputs (one place higher than last year). 🥇 Switzerland ranks first in innovation outputs (the same as the past four years). 🇨🇭 For Switzerland, three indicators have improved in the short term and eight indicators have worsened. The Global Innovation Index is published by the World Intellectual Property Organization, a specialised agency of the United Nations. 👉 Find the full economy brief for Switzerland here: https://lnkd.in/eZ-QZ88W

🤔 Do you ever wish someone could help you pitch your product to potential clients or investors in clear, simple English? Writing about what you do in a compelling way can make all the difference when it comes to engaging your audience. We are excited to announce we will be offering free one-to-one writing workshops through our partner Tate & Clayburn on how to pitch your product. The 25-minute sessions will be delivered by Co-Founder Rosie Tate and Writer and Editor Annabelle Dance. 📆 Wednesday 4 December 📍 Biopôle SA offices 👉 Spaces are limited, so be sure to book your free session here: https://lnkd.in/d43vPKvB

👏 Please join us in congratulating George Coukos, Director of Oncology at Lausanne University Hospital and Director of the Ludwig Institute for Cancer Research in Lausanne, on his election to the U.S. National Academy of Medicine (NAM).   Membership of NAM represents one of the highest honours issued to clinicians and scientists, recognising exceptional achievement and commitment to service in the fields of health and medicine. In naming Coukos as a member, NAM cited his landmark discoveries in the realm of tumour immunology and immunotherapy, which have helped to lay the groundwork for new cancer treatment pathways.   🧑🔬 We are so proud to count George among our members – his and his colleagues' work has not only established Lausanne as a global hotspot for oncology innovation, but also opened new doors for countless cancer patients. We can think of few people more deserving of this honour and recognition. Bravo, George and Ludwig Cancer Research!  

👋 We're thrilled to welcome INRA Group AG to Biopôle! 🏗️ INRA Group AG manufactures systems and pipes for the biochemical, pharmaceutical and chemical industries, setting standards in quality, innovation and technological progress. Meet the team (L–R)👇 Biopôle's Corporate Relations and Business Development Director Olivier Philippe with INRA Group AG and APACO AG's Sales Engineer Joao Korte Quinteiro, Head of Marketing Oriane Schaffhauser and Managing Director Torsten Weber. 👉 Find more information about the company and its work here: https://lnkd.in/d6je_gGA

💡 The survival rate for breast cancer patients is 99% when the cancer is caught very early, versus only 26% when the disease is detected at a later stage. That's just one example of why liquid biopsies, with their potential for disease monitoring and detection, could be a game-changer for cancer patients. For our October newsletter, Damien Lapray, Co-Founder of Hedera Dx, explains how liquid biopsies are being used now and how they have the potential to revolutionise cancer treatment. 👉 Read Damien's story and learn about Hedera Dx's work in the full article here: https://lnkd.in/evfK3-tg

Did you know that we list job opportunities in the life sciences on our website? Find your next job here! Currently open positions include: 👉 Biomarker Computational Scientist at HAYA Therapeutics 👉 Postdoctoral position in immunometabolism at University of Lausanne - UNIL 👉 PhD position in aging of hematopoietic stem cells at University of Lausanne - UNIL 👉 Project Manager at Vaccine Formulation Institute 👉 Lead Robotics Engineer (80~100%) at Emovo Care 👉 Clinical Affairs Expert at Novostia 👉 Quality Engineer at Novostia 👉 R&D Engineer at Novostia Find details and many more job opportunities on our dedicated jobs page: https://lnkd.in/gYi7VrN

⏳ Fewer than two weeks until Digital Health Day 2024. Have you already registered? Swiss Healthcare Startups's flagship event is back. Expect inspiring innovation journeys, behind-the-scenes insights and both success stories and valuable lessons from healthcare startups and corporates. Olivier Philippe, Corporate Relations and Business Development Director at Biopôle, will be attending! 👉 Discover more and register here: https://lnkd.in/gKSZfj2Z

🔬 Did you know that only a handful of liquid biopsy-based diagnostic tools have been approved by the FDA, even though scientists started researching them decades ago? A non-invasive method, they have the potential to revolutionise medical diagnostics, but there are still several obstacles to overcome. For our October newsletter, we had the pleasure of speaking to Sylvain Perriot, Founder of Lermed, about how liquid biopsies work and why they’ll be crucial as we enter the era of personalised medicine. 👉 Check out his insights in the full article here: https://lnkd.in/ewStYgbD

🚀 You may have heard about our Vanguard Accelerator programme, but what do you know about the Vanguard jury? The jury meets four times a year, with two carefully selected projects presented each time. Each year, the Vanguard Accelerator supports two to four projects. It's a committee of around thirty experts covering every part of the digital health value chain, including clinicians, nurses, hospitals, IT, regulators, investors, industry representatives, marketing and serial-entrepreneurs. But what do these people actually do? 💬 They offer 360° feedback on the projects submitted. 💡 They act as frontline experts, sharing their expertise in their fields. 🤝 They take on a leading role for projects. Although it's not an official part of the role, some jury members may even join the advisory boards of the companies enrolled in the accelerator, establishing a long-lasting relationship that goes well beyond the duration of the programme. 📆 Interested in applying for the Vanguard Accelerator? The latest deadline for applications is 8th November, and (virtual) presentations to the jury will take place on the afternoon of 27th November. 👉 Learn more here: https://lnkd.in/dGvFHdA5

🍂 Happy World Migratory Bird Day! When autumn sets in, we turn our eyes to our biotope, to see whether our seasonal visitors have returned to campus.   The pond is a winter haven for jack snipes – a rare species in Switzerland – and other animals. It's a wonderful spot for some bird-watching, in the upcoming weeks. Why not take a moment to pop down sometime to see who's flown in? 👀   A special thanks to the partners of this wonderful initiative that enabled our urban pond to live and develop over the last few years: Etat de Vaud, Ville de Lausanne et Commune d'Épalinges.